Buchumschlag

ADHD medicine consumption in Europe after COVID-19: catch-up or trend change?

Background: Although the COVID-19 pandemic and its implications have been associated with mental health services utilization and medication consumption, there is no longitudinal study on the long-term impact on ADHD medication use trends. Methods: This study examines the European ADHD medication con...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Gimbach, Sophie (VerfasserIn) , Vogel, Daniel (VerfasserIn) , Fried, Roland (VerfasserIn) , Faraone, Stephen V. (VerfasserIn) , Banaschewski, Tobias (VerfasserIn) , Buitelaar, Jan (VerfasserIn) , Döpfner, Manfred (VerfasserIn) , Ammer, Richard (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 09 February 2024
In: BMC psychiatry
Year: 2024, Jahrgang: 24, Heft: 1, Pages: 1-10
ISSN:1471-244X
DOI:10.1186/s12888-024-05505-9
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12888-024-05505-9
Volltext
Verfasserangaben:Sophie Gimbach, Daniel Vogel, Roland Fried, Stephen V. Faraone, Tobias Banaschewski, Jan Buitelaar, Manfred Döpfner and Richard Ammer
Beschreibung
Zusammenfassung:Background: Although the COVID-19 pandemic and its implications have been associated with mental health services utilization and medication consumption, there is no longitudinal study on the long-term impact on ADHD medication use trends. Methods: This study examines the European ADHD medication consumption in 2020 to 2022 compared to the predicted consumption assuming the persistence of pre-pandemic trends. Predictions are calculated using Seasonal Autoregressive Integrated Moving Average (SARIMA) models. Results: While European ADHD medication sales recorded a drop in 2020, they returned to the predicted level in 2021, even slightly exceeding it. In 2022, we found a clear exceedance of the predicted level by 16.4% on average at country level. Furthermore, the increase in consumption growth in the post-pandemic period (2021–2022) compared to the pre-pandemic period (2014–2019) was significant in 26 of the 28 European countries under consideration. Conclusion: There is strong evidence of a trend change in the ADHD medicine consumption growth throughout Europe after the COVID-19 pandemic.
Beschreibung:Gesehen am 25.06.2024
Beschreibung:Online Resource
ISSN:1471-244X
DOI:10.1186/s12888-024-05505-9

Ähnliche Einträge